A share price of ITeos Therapeutics Inc [ITOS] is currently trading at $7.85, up 13.44%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ITOS shares have gain 18.58% over the last week, with a monthly amount glided 38.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ITeos Therapeutics Inc [NASDAQ: ITOS] stock has seen the most recent analyst activity on May 13, 2025, when JP Morgan downgraded its rating to a Neutral. Previously, Wells Fargo started tracking the stock with Overweight rating on August 13, 2024, and set its price target to $31. On May 05, 2021, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $45 on October 08, 2020. Wedbush initiated its recommendation with a Outperform and recommended $45 as its price target on August 18, 2020. SVB Leerink started tracking with a Outperform rating for this stock on August 18, 2020, and assigned it a price target of $45. In a note dated August 18, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $50 on this stock.
ITeos Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.80 and $18.70. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. ITeos Therapeutics Inc [NASDAQ: ITOS] shares were valued at $7.85 at the most recent close of the market. An investor can expect a potential return of 116.56% based on the average ITOS price forecast.
Analyzing the ITOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -4.35%, Pretax Profit Margin comes in at -3.41%, and Net Profit Margin reading is -3.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.21 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.55 points at the first support level, and at 7.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.33, and for the 2nd resistance point, it is at 8.80.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ITeos Therapeutics Inc [NASDAQ:ITOS] is 14.13. In addition, the Quick Ratio stands at 14.13 and the Cash Ratio stands at 4.12. Considering the valuation of this stock, the price to sales ratio is 8.58, the price to book ratio is 0.53.
Transactions by insiders
Recent insider trading involved Gall Matthew, Chief Financial Officer, that happened on Nov 19 ’24 when 5000.0 shares were purchased.
